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Inhibition of Cancer'Cell Stickiness by the
Blocking of Platelet Aggregation
H. GASTPAR
SUMMARY HOW CANCER CELLS CAUSE OBSTRUCTION
Fig. 1. Conversion of a tumour cell embolus to a meta-
stasis (Fisher and Fisherr.).
The dynamics of the early stage of metastasis formation,
first demonstrated by Wood et al.' by intravital microcine-
matography, can be classified into three phases (Fig. I):
1. The attachment of sticky cancer cells to the endothe-
lium.
2. The aggregation of platelets and leucocytes round








Cancer cells display a varying tendency to stick to the
vascular endothelium. Platelets may aggregate on sticky
cancer cells during their circulation. Such a tumour
attaches more readily to the endothelium. Once tumour
cells are attached, the cross-section of the small vessels is
diminished, thus obstructing blood flow. Turbulence results
behind the obstruction. Thrombocytes and leucocytes are
attracted into this turbulence and preferably aggregate
there. Within minutes they become enmeshed in a fibrin
clot. In a few hours, the lodged cancer cells are able to
penetrate the vessel wall, often following an emigrating
lymphocyte. 1o These cancer cells either proliferate in the
extravascular tissue or traverse the interstitial space and
re-enter the lymphatics, analogous to the continuous recir-
culation of lymphocytes from the blood back into the
lymph, as demonstrated by Gowans. ll
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The mechanisms of the early stage of metastasis forma-
tion by blood-borne cancer cells is described. Abnormal
platelet aggregation, alteration of coagulation and fibrino-
lysis play an important part.
The reducing effect on cancer cell stickiness of dipyrida-
mole, some of its derivative compounds and two other
vasodilating agents were investigated in animals. A clini-
cal trial was started 15 months ago with the dipyridamole
compound RA 233 in patients with sarcoma of the head
and neck region.
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The first step in the formation of metastasis is the secure
attachment of blood-borne cancer celis to the endothelium
of capillaries. In experimental animals, as in humans, the
vascular endothelium represents the universal host of -
and barrier to - circulating cancer cells.! Therefore the
interaction between endothelium and cancer cells is a
focal point of the metastasis problem.
In 1903 Schmidf was the first to demonstrate cancer
cells in the arterioles of lungs of deceased cancer patients;
these cells were attached to the vascular wall and sur-
rounded by conglutinated platelets, leucocytes and a dense
network of fibrin. These observations were confirmed by
other investigators with histological studies of human
postmortem material'" and experimental systems:,'·7
Since the cancer cell attachment to the vascular endo-
thelium and the consequent thrombus formation are
dynamic events, the pathogenesis of the early stage of
metastasis production by blood-borne cancer cells cannot
be evaluated by the interpretation of the static morpholo-
gical findings alone.
Progress was made by viewing the sequence of events
in metastasis formation using intravital capillary micro-
scopy. The intravital microcinematographic recordings of
Wood et al"" and Gastpar et al." are particularly valuable.
They demonstrated the fate of intravenously transplanted
single ascites cells in V,-carcinoma, Lewis-carcinoma-150,
Walker-256-carcinosarcoma and Yoshida-sarcoma in
arterioles, capillaries and venules of the ear chamber of
rabbits, the mesentery of rats and the peritoneum of mice.
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3. The penetration of the vessel wall by the arrested
cancer cells and extravascular proliferation.
The initial adherence of embolic cancer cells to intact
vascular endothelium observed in vivo is independent of
capillary diameter, rate of the blood flow or vasomotor
activity.I." The labile capillaries do not function as simple
mechanical filters of embolic cancer cells. Rather, the
lodgement of these circn!ating cancer cells on the endothe-
lium depends mainly on their 'stickiness',IJ a specific in-
digenous physicochemical property of the cell surface"
related to its thromboplastic activity.I.15'" Its influence on
metastasis production has been demonstrated with particu-
lar distinctness in various strains of rat ascites hepatomata
by Kojima and Sakai." The strain-specific cellular sticki-
ness in vitro was closely related to the strain-specific fre-
quency pattern of pulmonary metastasis. Furthermore, it
was found that the stickiness of tumour cells decreased
significantly by in vitro pretreatment with trypsin and
heparin."
reducing their stickiness, there are certain experimental
factors which enhance the stickiness of cancer cells,
leucocytes, thrombocytes or endothelium, and/ or produce
potential hypercoagulability. Examples are stress, cortisone
treatment, trauma, hyperlipaemia, antifibrinolytic agents,
endotoxin, radiotherapy and sublethal doses of cytostatic
drugs.""'" These agents generally may favour metastasis
production from embolic tumour cells, as demonstrated
in Fig. 2. On the left are noted factors that may enhance
this event. On the right are listed agents that have been
investigated for their ability to reduce the inc;idence of
metastasis production in certain experimental tumours.
DIPYRIDAMOLE
Since thrombocytes play an important role in the mecha-
nism of tumour cell lodgement and subsequent thrombus
formation, we assumed that substances which block aggre-
gation of thrombocytes also assist in the inhibition of
lodgement of tumour cells.'· Dipyridamole (Fig. 3) has
Fig. 3. Chemical structures of dipyridamole (RA 8) and




Since the impressive studies of Lawrence et al."'" and
Cliffton and Grossi, ,. evidence has accumulated showing
that anticoagulants and fibrinolytic drugs interfere with
the initial adherence of cancer cells to the vascular endothe-
lium and their enmesbment in a fibrin clot. These drugs
reduce the incidence of metastasis production of some
experimental tumours.'·","2 Furthermore, it might be con-
jectured that anticoagulants promote the traversing of
cancer cells via the interstitial route, at the same time
preventing their extravascular proliferation. '3
In contrast to the anticoagulant and fibrinolytic agents
which exert a protective effect against the formation of
metastases from blood-borne cancer cells by means of
RA 255
RA ]JJ
been found to reduce the spontaneous aggregation of
platelets,'· to decrease thrombus formation in response to
vascular injury in rabbits," to alter the electrophoretic
mobility of platelets in response to norepinephrine,'6 and
to diminish platelet adhesiveness in patients with coronary
artery disease"'" and renal disease."'·30 Some other
pyrimido-pyrimidine compounds have also been shpwn to
influence the platelet behaviour in vitro and in vivo."''''
Some of the effects of these drugs on platelet aggregation,
bleeding time, blood pressure and thrombus formation are
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Fig. 2. Proposed scheme for metastasis formation from




We have determined the influence of some new pyrimido-
pyrimidine derivatives on the stickiness of circulating
tumour cells by intravital microscopy in the mesentery of
rats.'·'" The mesentery of Wistar rats of 150 - 200 g body'
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TABLE J. ACUTE TOXICITY AND THE EFFECTS OF 4 PYRIMIDO-PYRIMIDINE COMPOUNDS ON ADP- AND COLLAGEN-
INDUCED AGGREGATION (BORN TEST) AND RETENTION OF PLATELETS (MORRIS TEST), BLEEDING TIME,





BP reduction (2 mg/kg IV)
Acute toxicity mice LDso
Ra 8 Ra 233 VK 744 Ra 255
ADP
1st phase 0 51/"c 27% 21%
5 X 10·smoJ.
Oral 0 70°fc, 65% 49/"0
Collagen 50/"0 inhibition 5 X 10-' 3 X 10-' 6 X 10.... 5 X 10....
3 X lO-smol 48% 39/"o 76/"0 31/"0
10-'mol 15% 15/"0 35/"o 10%
5 X 10....mol 0 0 0
hour after 10 mg/kg oral 8,9 min 7,8 min 11,4 min 11,9 min
control: 4,0 min +-0,42 -+-0,78 -+-0,46 -+-0,64 -+-0,36
hour after 10 mg/kg oral <:6/"0 41% 62% 72%
(20 mg)
mmHg -52 -23 -8 -32
Duration (min) 58 14 1 5
IV 150 mg/kg 148 mg/kg 115 mg/kg 216 mg/kg
Oral >2 g/kg 465 mg/kg 680 'mg/kg >3 g/kg
mass was dissected after anaesthesia with cWoral hydrate.
Two millilitres of a suspension containing 1 x 109 fiuoro-
chromated Walker-256-carcinosarcoma cells were slowly
injected into a polyethylene catheter inserted into the
jugular vein. Solutions of various doses of dipyridamole
(RA 8) and the pyrimido-pyrimidine compounds RA 233,
RA 255 and VK 744 were injected into the catheter 5
minutes before tumour cell transplantation. The platelet
count in the venous blood of the animals was determined
10 minutes before and 20 minutes after tumour cell
transplantation.
As demonstrated in Table 11, within 5 - 10 minutes after
the infusion, fatal tumour cell embolism of the lungs was
observed in 60% of the control animals (column 4). This
was due to the blockade of pulmonary capillaries and
arterioles by lodged and clumped tumour cells, which in
TABLE 11. EFFECT OF 4 PYRIMIDO-PYRIMIDINE DERIVATIVES
ON PULMONARY TUMOUR CELL EMBOLISM IN RATS AFTER
INTRAVENOUS TRANSPLANTATION OF 1 X 10' WALKER-
256-CARCINOSARCOMA CELLS VIA JUGULAR VEIN"
some instances produced occlusion of a complete pill-
monary segment. This lethal rate was diminished to 27%
by intravenous injection of 10 mg/ kg of dipyridamole and
to zero by RA 233, RA 255 and VK 744.
The dose-response relationships of these substances on
fatal tumour cell embolism of the lungs was quantified
by a probit analysis'· as illustrated in Fig. 4. The signifi-
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Fig. 4. Probit regression lines for effect of 4 pyrimido-
pyrimidine compounds on tumour cell embolism mortality
in rats.
Substance Dose Mortality Mortality
c%)
Controls 36/60 60
RA 8t 3 mg/kg 19/40 48
RA 8t 6 mg/kg 14/40 35
'RA 8t 10 mg/kg 8/30 27
RA 233 3 mg/kg 12/40 30
RA 233 6 mg/kg 3/30 10
RA 233 10 mg/kg 0/20
RA 255 3 mg/kg 10/40 25
RA 255 6 mg/kg 2/40 5
RA 255 10 mg/kg 0/40
VK 744 3 mg/kg 05/30 17
VK 744 6 mg/kg 1/30 3
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TABLE Ill. EFFECT OF 4 PYRIMIDO-PYRIMIDINE COMPOUNDS ON THE PLATELET COUNT IN SURVIVING RATS
AFTER INTRAVENOUS TRANSPLANTATION OF 1 X 10' WALKER-256-CARCINOSARCOMA CELLRll
Platelet count before trial Platelet count after trial
Substance, No. of Mean Standard Standard Mean Standard Standard Reduction
dose survivors value deviation error value deviation error (%)
Controls 24 702,1 56,31 11,49 169,2 74,45 15,19 -75,9
RA 8t
3 mg/kg 21 724,1 79,36 17,32 224,5 92,15 20,11 -69,0
10 mg/kg 22 729,7 55,98 11,93 297,8 74,50 15,88 -59,2
RA 233
3 mg/kg 28 705,6 42,94 8,11 273,5 71,02 13,42 -61,2
10 mg/kg 20 708,6 39,60 8,86 615,0 55,10 12,32 -14,6
RA 255
3 mg/kg 30 708,2 33,05 6,04 289,9 57,48 10,48 -59,1
10 mg/kg 40 703,6 28,14 4,45 696,0 39,14 6,19 - 1,1
VK 744
3 mg/kg 25 709,0 36,21 7,24 512,4 31,77 6,35 -27,7
10 mg/kg 30 693,9 30,17 ,5,50 687,9 34,22 6,24 - 0,9
t Dipyridamole (Persanlin).
examined. In contrast to normal probit analysis the portion
of surviving animal represent percentage points of the
diagram; the arrows indicate lOO~~ response rates.
The platelet count in the venous blood of untreated
animals and those treated with low doses was significantly
reduced compared with animals who received higher doses
of the pyrimido-pyrimidine derivatives. Table III presents
mean values, standard deviations, standard errors and per-
centage reduction for the different dose groups and test
substances. The summarising statistics, however, must be
interpreted with some caution, because the samples from
which they were calculated, in most instances, are selected
from death cases. Nevertheless, a trend may be recognised,
and the standard errors will give some hint concerning
the significance of the differences. This may be interpreted
by a protection of the rats sufficiently treated against
lethal tumour cell embolism of the lungs, effected by an
inhibition of the platelet aggregation.
The criterion for the reaction of the test substances on
the thrombocyte adhesiveness and aggregation was the num-
ber of infused tumour cells that could be detected in a
certain area of I cm', showing adherence to the vascular
endothelium during a period of 30 minutes of observation.
Table IV notes the number of the adhering tumour cells.
TABLE IV. THE EFFECT OF 4 PYRIMIDO-PYRIMIDINE
DERIVATIVES ON THE INITIAL LATENT ADHERENCE OF
TUMOUR CELLS TO VASCULAR ENDOTHELIUM IN THE
MESENTERY OF RATS AFTER INTRAVENOUS TRANSPLAN-
TATION OF 1 X 10' WALKER-256-CARCINOSARCOMA
CELLS VIA JUGULAR VEIN"
t Dipyridamole (Persanlin).
Fig. 5. Dose-response relationship for the effect of RA 8,
RA 233, RA 255 and VK 744 on latent cancer cell sticki-
ness in the mesentery of rats.
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In the controls the mean value was 57 cells per animal,.
specified in column 4.
Dipyridamole and the other tested pyrimido-pyrimidine
derivatives caused a marked reduction of tumour cell
adherence. The compounds RA 233, RA 255 and VK
744 were the most potent ones.
The dose-response relationships for cancer cell stickiness
data were investigated by means of variance analysis
(Fig. 5). Although the distribution of the data of the
highest dosage groups may not meet the criteria of this
analysis, it will serve to introduce only a small bias into
the results because of the relative inaccuracy of the analy-
sis of variance technique. The dose-response curves are
displayed graphically by plotting the mean response against
the logarithm of the stimulus level. It may be seen that
the differences among the dosage groups for RA 8, RA
233, RA 255 and VK 744 are higWy significant. These
differences may be explained by a linear trend component,
so that linear dose-response relationship can be assumed.
The order of effectiveness of the test substances was the
same as in the mortality from pulmonary embolism.
SH 869, BENCYCLANE AND BL 191
Recent unpublished experiments with SH 869, a new
pyrimido-pyrimidine derivative, as well as with bencyclane-
hydrogen fumarate and the methylxanthine derivative BL
191, two vasodilating substances, showed that these sub-
TABLE V. EFFECT OF BENCYCLANE, BL 191 AND SH 869
ON PULMONARY TUMOUR CELL EMBOUSM IN RATS
AFTER INTRAVENOUS TRANSPLANTATION OF 1 X 10'
WALKER-2S6-CARCINOSARCOMA CELLS VIA JUGULAR VEIN
Mortality rate
Substance, dose Mortality (%)
Controls 2S/40 62,S
Bencyclane'
3 mg/kg 14/30 46,7
6 mg/kg 9/30 30,0
12 mg/kg 4/30 13,3
BL 191t
3 mg/kg 14/30 46,7
6 mg/kg 10/30 33,3
12 mg/kg S/30 16,7
SH 869 intragastrici
2 mg/kg 6/30 20,0
4 mg/kg 2/30 6,7
8 mg/kg 0/30
SH 869 intravenousi
1 mg/kg 1.5/30 SO,O
2 mg/kg 8/30 28,9
4 mg/kg 4/30 13,3
• N-(3-(1 bencyl-cycloheptyl-oxy) propyl) -N.N.-dimethyl-ammonium hy·
drogenfumarate.
t 3.7-d imethyl-1- (5-oxo-hexyl) -xa nth i ne.
2-pi pe ra c i ny1-4-th iomor ph 01 ino-py ri do (3 .2-d) pyri m id ine-$U Iphate-t ri h y-
drate.
stances are also able to reduce the pulmonary embolism
mortality, to hinder platelet aggregation on' circulating
sticky cancer cells, and to inhibit their attachment to the
endothelium.
As demonstrated in Table V, the rate of lethal tumour
cell embolism was diminished from 62,5% to l7.% by 12
mg/kg BL 191, to 13.% by 12 mg/kg bencyclane and 4
mg/kg SH 869 respectively administered intravenously,
and to zero by 8 mg/kg SH 869 administered intra-
gastrically. The dose-response curves for the effect of
these substances on fatal tumour cell embolism also were
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Fig. 6. Probit regression lines for the effect of bencyclane,
BL 191, and SH 869 on tumour ceU embolism mortality
in rats.
The platelet count in the venous blood of untreated
animals and those treated with insufficient doses was signi-
ficantly reduced compared with animals which received
the highest dose groups of the test substances (Table VD-
The most effective protection of the platelet count against
reduction resulted after intragastric administration of 8
mg/kg SH 869.
The number of adhering tumour cells is listed in Table
VII. In the controls the mean value was 54 cells per
animal, specified in column 3. Bencyclane and BL 191
caused a marked reduction of tumour cell adherence, to a
mean of 29 and 24 cells respectively per animaL With
intravenous SH 869 the number of lodged tumour cells
dropped to a mean of 10 cells and to a mean of only 1
cell per animal after intragastric administration.
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TABLE VI. EFFECT OF SH 869 (INTRAVENOUS AND INTRAGASTRIC ADMINISTRATION), BENCYCLANE AND BL. 191 ON
THE PLATELET COUNT IN SURVIVING RATS AFTER INTRAVENOUS TRANSPLANTATION OF 1 X 10' WALKER-256-
CARCINOSARCOMA CELLS
Platelet count before trial Platelet count after trial
No. of Mean Standard Standard Mean Standard Standard Reduction
Substance, dose survivors value deviation error value deviation error C%)
Controls 15 698 16 4 165 20 S -76,4
SH 869 intravenous
1 mgjkg 15 674 21 5 298 18 S -55,8
4 mgjkg 26 682 26 5 579 30 6 ·-15,1
SH 869 intragastric
2 mgjkg 24 703 20 4 541 31 6 -23,1
8 mgjkg 30 692 23 4 688 21 4 - 0,6
Bencyc1ane
3 mgjkg 16 719 18 3 247 21 8 . -65,6
12 mgjkg 26 709 24 3 324 15 5 -52,9
SL 191
3 mgjkg 16 702 14 2 235 15 6 -66,5
12 mgjkg 25 683 16 2 356 29 8 -48,0
TABLE VII. EFFECT OF BENCYCLANE, BL 191 AND SH 869
ON THE INITIAL ADHERENCE OF TUMOUR CELLS TO
VASCULAR ENDOTHELIUM IN THE MESENTERY OF RATS
AFTER INTRAVENOUS TRANSPLANTATION OF 1 X 10'
WALKER-256-CARCINOSARCOMA CELLS VIA JUGULAR VEIN
The dose-response relationship for cancer cell stickiness,
investigated by means of variance analysis, is demonstrated
in Fig. 7. It may be seen that the differences among the
dosage groups are highly significant, so that linear dose-
response relationship for all three substances can be
assumed.
It is interesting to note that the new pyrimido-pyrimidine
compound SH 869 was more efficacious when administered
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Fig. 7. Dose-response relationship for the effect of ben-
cyclane, BL 191 and SH 869 on latent cancer ceJ stickiness
in the mesentery of rats.
may be explained by a high absorption rate and a quick
transformat;on into a more effective metabolite.
BencycIane, BL 191 and the pyrimido-pyrimidine de-
rivatives used, especially the compounds RA 233, RA 255,
VK 744 and SH 869, were able to interfere with the
dynamic interaction between sticky tumour cells and vas-
cular endothelium, just as heparin and fibrinolysin do, but
at an earlier stage. They inhibited platelet adhesiveness and
aggregation to circulating sticky tumour cells and signifi-
cantly inhibited their attachment to the endothelium. Also,
these compounds hindered the platelet aggregation round
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formation. Further proof of this is that some of these
substances prevented lethal pulmonary tumour cell embo-
lism which occurred in 60 - 62,5 % of the controls. .
It remains to be seen whether other animal tumours can
be affected in the same manner. It should also be deter-
mined whether these substances can significantly reduce
the rate of uptake and the frequency pattern of tumour
metastasis.
that metastases or new tumours do occur within one year
in 15 - 35% of all patients. By the same token, I realise
that the number of patients in this group is small and
the time of medication and observation is short, but until
now none of our patients has developed clinical signs of
a local recurrence or of a metastasis. The clinical tolerance
of RA 233 is good and no side-effects appeared. This is
encouraging as an effective beginning of metastasis prophy-
laxis in cancer.
CLINICAL APPLICATION
12 reticulum cell sarcoma, 3 lymphosarcoma, 3 Hodgkin's sarcoma,
2 melanosarcoma. 2 angioplastic sarcoma, 1 anaplastic sarcoma, 1
spinocellular sarcoma, 1 rhabdomyosarcoma.
'Oral lethal doses in guinea pigs and rats could not be assessed; they
are in excess of 3 g/kg body mass. In mice, oral LD.. was 465
mg/kg body mass Chronic toxicity was studied in rats and dogs.
Pathological alterations due to drug administration could not be demon-
strated. Teratogenic investigations with increasing doses in rats and dogs
showed negative results.
TABLE VIII. METASTASIS PROPHYLAXIS WITH DAILY LONG-
TERM THERAPY OF THE PYRIMIDO-PYRIMIDINE COMPOUND
RA 233 IN 25 PATIENTS WITH SARCOMA OF THE HEAD AND
NECKt
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in 25 patients with sarcoma of the head and neck region
(after surgery and radiation therapy) in a daily dosage of
3 x 250 mg and 3 x 500 mg respectively (Table Vll!).
Since this was not a controlled study, results should be
treated with some reservation. It is, however, my experience
On the basis of our experimental data and because the
clinical and toxicological conditions of the pyrimido-
pyrimidine compound RA 233 allowed a daily long-term
. therapy,* we started a controlled clinical study on meta-
stasis prophylaxis 15 months ago. We used this substance
9
